Purchase Order 75F40126P00132

<p>The Food and Drug Administration awarded a purchase order to Bioivt, LLC for cryopreserved hepatocytes on August 17, 2023, with a ceiling value of $16,179.20. Performance takes place in Silver Spring, Maryland. The order, issued as a firm fixed-price acquisition with no set-aside designation, has an ultimate completion date of August 16, 2024.</p>

This purchase order contract was awarded by the National Institutes of Health's National Center for Advancing Translational Sciences to Life Technologies Corporation for the delivery of 50 vials of human spheroid-qualified hepatocytes. As described in the original solicitation, these liver cells will support the National Institute on Drug Abuse's Antiviral Program for Pandemics by enabling the continued identification of direct-acting antivirals and development of microphysiological systems...

The Food and Drug Administration (FDA) awarded a $91,630 firm-fixed-price purchase order contract to Discovery Life Sciences, LLC, a small disadvantaged business, for the delivery of 110 vials of primary cryopreserved human hepatocytes. This requirement supports the FDA's National Center of Toxicological Research (NCTR) Division of Biochemical Toxicology's research into drug toxicity and metabolic enzymes. The contract has a period of performance through August 19, 2024 and was awarded under a...

This is a firm fixed-price purchase order awarded by the National Center for Advancing Translational Sciences (NCATS), a civilian agency within the U.S. Department of Health and Human Services, to Life Technologies Corporation, a manufacturer of scientific instruments, reagents, and consumables. The $24,262.29 contract is for the delivery of primary human hepatocytes, which are a critical reagent used in biomedical research supported by NCATS. This contract is not associated with any set-aside...

This is a firm fixed-price purchase order contract awarded by the Food and Drug Administration (FDA) to Discovery Life Sciences, LLC, a small disadvantaged business, on August 2, 2022. The contract has a ceiling value of $48,945.00 and a completion date of November 1, 2022. The contract is for the procurement of primary human hepatocytes and media, as requested in the FDA's Sources Sought Notice FDA-SSN-1252684. Discovery Life Sciences has over a decade of experience supporting federal agencies'...

This is a firm fixed-price purchase order awarded by the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH), to BioIVT, LLC for the procurement of various Hepatopac sample well plates, including human, mouse, and stromal plates, as well as maintenance and application media. The total ceiling value of the contract is $27,249.00, with an anticipated 60-day delivery after receipt of order. The purchase order was awarded on a...

The Food and Drug Administration (FDA) awarded a $27,120 firm fixed-price purchase order to Phoenixbio Co., LTD., a Japan-based contract research organization, on March 17, 2022, with an ultimate completion date of September 6, 2022. The contract covers the provision of human hepatocyte cultures to be delivered to Silver Spring, Maryland. No set-aside designation was applied to this award, and Phoenixbio Co., LTD. served as the prime contractor with no subcontracting indicated. Phoenixbio Co.,...

This is a $15,540.00 firm fixed price delivery order contract awarded by the Defense Health Agency to Bioivt, LLC, a for-profit limited liability company. The contract is to provide male cynomolgus monkey hepatocytes and male rhesus monkey hepatocytes to support in vitro assays. The contract has a period of performance through September 30, 2024 and was awarded on June 18, 2024. There is no set-aside designation for this contract. Bioivt, LLC has past experience providing biological materials...

<p>The Department of the Army Medical Command awarded a $105,000 firm fixed price delivery order to Bioivt, LLC of Westbury, New York on July 7, 2021. The order calls for the delivery of monkey cryoplateable hepatocytes by July 13, 2021. No set-aside designation was used for this contract. Bioivt will provide the hepatocytes to support research at the Army Medical Command. As the prime contractor, Bioivt will be solely responsible for fulfilling the delivery order requirements.</p>

The Food and Drug Administration awarded a purchase order to 28Bio, Inc. for $143,020.98 to conduct central nervous system 3D brain organoid neuropharmacological analysis under Executive Order 14398, with an award date of August 1, 2026 and completion date of April 30, 2027. Performance takes place in Metairie, Louisiana. The work involves functional examination of neuromodulatory effects of a marketed small molecule drug using human CNS 3D brain organoids, including acute and chronic...